AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9587133
Drug: Malignant lymphoma/multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Malignant lymphoma/multiple myeloma (ML/MM)
Trial: 3130925
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 60 mg APD intravenously
Trial: 3130925
Drug: Daily doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily doses of 30 mg APD (two days) or 15 mg (four days)
Trial: 31290697
Drug: Juice-based targeted
RxNorm normalized name: tamarind juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Juice-based targeted medical nutrition (TMN) supplement (∼200 kcal; 10 g whey protein; ≥2.0 g eicosapentaenoic acid/docosahexaenoic acid in fish oil; and 10 μg 25-hydroxy-vitamin D3)
Trial: 19181969
Drug: Nonoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative treatment with orthosis (22 patients)
Trial: 11804384
Drug: Various treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various treatment approaches (surgery, radiation, chemotherapy, BSC)
Trial: 9440748
Drug: Single-dose (pulse-intensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose (pulse-intensive [PI]) treatment with dactinomycin for low-risk patients
Trial: 9440748
Drug: Divided-dose (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Divided-dose (standard [STD]) treatment with dactinomycin for low-risk patients
Trial: 9440748
Drug: Single-dose (pulse-intensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose (pulse-intensive [PI]) treatment with doxorubicin for high-risk patients
Trial: 9440748
Drug: Divided-dose (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Divided-dose (standard [STD]) treatment with doxorubicin for high-risk patients
Trial: 2684073
Drug: Betaxolol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betaxolol (20 mg once daily)
Trial: 2684073
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Betaxolol and Chlorthalidone
Trial: 31000379
Drug: Lidocaine and
RxNorm normalized name: Lidocaine and Tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine and phenylephrine nasal spray (10 mg lidocaine and 1 mg phenylephrine for children weighing 6–12 kg; 20 mg lidocaine and 2 mg phenylephrine for children weighing >12 kg)
Trial: 31000379
Drug: 0.9% sodium
RxNorm normalized name: LMD with 0.9% Sodium Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride placebo nasal spray
Trial: 31000379
Drug: Lidocaine and
RxNorm normalized name: Lidocaine and Tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine and phenylephrine nasal spray
Trial: 25540891
Drug: EBO vaccine
RxNorm normalized name: ERVEBO Vaccine Suspension for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EBO vaccine
Trial: 25540891
Drug: MAR vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAR vaccine
Trial: 20140352
Drug: 23-valent polysaccharide
RxNorm normalized name: pneumococcal 23-valent polysaccharide vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 23-valent polysaccharide vaccine during pregnancy (Group 1)
Trial: 20140352
Drug: 23-valent polysaccharide
RxNorm normalized name: pneumococcal 23-valent polysaccharide vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 23-valent polysaccharide vaccine after pregnancy (Group 2)
Trial: 20140352
Drug: No vaccine
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No vaccine (Group 3)
Trial: 9604230
Drug: Weight-adjusted LT4-dose
RxNorm normalized name: LT4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Weight-adjusted LT4-dose in combination with 150 micrograms iodide (group A)
Trial: 9604230
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of 100 micrograms LT4 plus 100 micrograms iodide (group B)
Trial: 1655350
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid 150 mg/die i.v. for 10 days
Trial: 1655350
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid 1,000 mg/die i.v. for 10 days
Trial: 31529492
Drug: Conventional therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapies (physician's choice with either methotrexate or bexarotene)
Trial: 27955919
Drug: Elosulfase alfa
RxNorm normalized name: Elosulfase alfa
DrugBank: Elosulfase alfa (DB09051)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Elosulfase alfa (2.0 mg/kg) administered weekly or every other week for 120 weeks
Trial: 21309194
Drug: Fasting glucose
RxNorm normalized name: FAST TAKE (GLUCOSE) METER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting glucose 90 mg/dL or greater
Trial: 21309194
Drug: 1 hour
RxNorm normalized name: Product containing precisely estradiol 312.5 nanogram/1 hour prolonged-release vaginal ring (clinical drug)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 hour glucose 165 mg/dL or greater
Trial: 21309194
Drug: 1 hour
RxNorm normalized name: Product containing precisely estradiol 312.5 nanogram/1 hour prolonged-release vaginal ring (clinical drug)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 hour glucose 150 mg/dL or greater
Trial: 15268892
Drug: Risedronate (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate (30 mg daily for 10 doses during the first 2 weeks, then once a week for 12 weeks)
Trial: 11296884
Drug: Single low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single low-dose administration of 60 mg dihydrocodeine
Trial: 11296884
Drug: Chronic high-dosage
RxNorm normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic high-dosage administration of dihydrocodeine
Trial: 8037259
Drug: Alprazolam (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (1 mg p.o.)
Trial: 4309863
Drug: Topical oral
RxNorm normalized name: aloe vera topical oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical oral corticosteroids (0.3‐0.4 mg. of betamethasone disodium phosphate daily)
Trial: 4309863
Drug: Topical oral
RxNorm normalized name: aloe vera topical oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical oral hydrocortisone hemisuccinate (10 mg. daily for up to three years)
Trial: 4309863
Drug: Topical oral
RxNorm normalized name: aloe vera topical oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical oral betamethasone 17‐valerate (0.4 mg. per day)
Trial: 4309863
Drug: Topical oral
RxNorm normalized name: aloe vera topical oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical oral hydrocortisone hemisuccinate and betamethasone 17‐valerate
Trial: 4309863
Drug: Topical oral
RxNorm normalized name: aloe vera topical oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical oral betamethasone disodium phosphate
Trial: 28980935
Drug: Lactobacillus acidophilus
RxNorm normalized name: Lactobacillus acidophilus
DrugBank: Lactobacillus acidophilus (DB15823)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus acidophilus (5x10^9 cfu/capsule) for 8 weeks
Trial: 23982366
Drug: 400 mg/d
RxNorm normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/d of sofosbuvir and weight‐based ribavirin for 24 weeks
Trial: 23982366
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of sofosbuvir with weight‐based ribavirin for 24 weeks
Trial: 23982366
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of sofosbuvir with low‐dose 600 mg/d of ribavirin for 24 weeks
Trial: 17392695
Drug: Isoflavone intake
RxNorm normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavone intake <90 mg/day
Trial: 10895746
Drug: Triamcinolone 20
RxNorm normalized name: triamcinolone 20 mg/mL injectable suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triamcinolone 20 mg
Trial: 10895746
Drug: No steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No steroid (0 mg)
Trial: 3310826
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 0.030 mg ethinylestradiol and 0.150 mg levonorgestrel
Trial: 3310826
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 0.030 mg ethinylestradiol and 0.150 mg desogestrel
Trial: 3310826
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (0.030 mg ethinylestradiol and 0.150 mg levonorgestrel)
Trial: 3310826
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (0.030 mg ethinylestradiol and 0.150 mg desogestrel)
Trial: 31948767
Drug: Ivermectin MDA
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivermectin MDA with three consecutive daily doses of 300 μg/kg (3×300 μg/kg)
Trial: 27921413
Drug: Low-dose phototherapy
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose phototherapy (mixture of UVA, UVB, and visible light)
Trial: 24693926
Drug: Standardized treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized treatment at the hospital plus a weekly session with a peer of their choice (Experimental group)
Trial: 24693926
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment at the hospital plus a weekly interactive and physical activity session (Comparison group)
Trial: 23799702
Drug: Prescription plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription plus referral intervention (n = 12)
Trial: 23799702
Drug: Prescription only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription only intervention (n = 12)
Trial: 18480190
Drug: Multidisciplinary rehabilitation
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary rehabilitation (physical training twice weekly + cognitive-behavioral training once weekly)
Trial: 18480190
Drug: Physical training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical training (twice weekly)
Trial: 15321086
Drug: i.v. glycopyrrolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. glycopyrrolate 4.0 microg/kg (group G)
Trial: 9014624
Drug: Lignocaine 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lignocaine 1% (5 ml) instilled hourly for 12 h
Trial: 9014624
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline (5 ml) instilled hourly for 12 h
Trial: 3883172
Drug: Oral methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral methotrexate (2.5 to 5 mg every 12 hours for three doses weekly)
Trial: 27624603
Drug: Conventional loop
RxNorm normalized name: LOOP OSTOMY ROD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional loop diuretics (Group C)
Trial: 25373935
Drug: Formula containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formula containing high sn-2 palmitate plus 3 g/L oligofructose (sn-2+OF; n=55)
Trial: 22932428
Drug: i.v. amphetamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. amphetamine dose of 0.3 mg/kg bodyweight
Trial: 18444166
Drug: Topical perillyl
RxNorm normalized name: perilla frutescens top
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical perillyl alcohol (POH) cream (0.76% wt/wt) applied twice daily for 30 days
Trial: 18444166
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream applied twice daily for 30 days
Trial: 359140
Drug: Exercise treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise treatment (low-level physical activity sessions, 14 of 18 sessions over 6 weeks)
Trial: 28341259
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (1000 IU daily) and isokinetic training (3 times per week at 150°/s)
Trial: 28341259
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (1000 IU daily) and isokinetic training
Trial: 19457978
Drug: Physiotherapy staff
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Physiotherapy staff recording of treatment time
Trial: 19457978
Drug: Video recording
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Video recording of treatment time
Trial: 16710580
Drug: Topical tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tacrolimus 0.1% ointment 4 times daily
Trial: 16710580
Drug: Triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide 0.1% ointment 4 times daily
Trial: 15471389
Drug: Aspirin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (250 mg on admission, then 125 mg/day)
Trial: 15471389
Drug: Cardiomagnil (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiomagnil (150 mg on admission, then 75 mg/day)
Trial: 15471389
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of clopidogrel (75 mg/day) and cardiomagnil (75 mg/day)
Trial: 11204665
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with novel agents (e.g., thymidylate synthase inhibitors, epidermal growth factor‐receptor antagonists, microtubule interactive agents)
Trial: 9278830
Drug: ondansetron 4
RxNorm normalized name: ondansetron 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ondansetron 4 mg intravenously (IV)
Trial: 9278830
Drug: droperidol 25
RxNorm normalized name: Droperidol
DrugBank: Droperidol (DB00450)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: droperidol 25 mcg/kg i.v.
Trial: 8318783
Drug: Intraperitoneal injection
RxNorm normalized name: CALCIUM GLUCONATE 23 g in 100 mL INTRAPERITONEAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal injection of DDP at doses of 110 mg/m2
Trial: 8318783
Drug: Intraperitoneal injection
RxNorm normalized name: CALCIUM GLUCONATE 23 g in 100 mL INTRAPERITONEAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal injection of DDP at doses of 70 mg/m2
Trial: 8318783
Drug: Intraperitoneal injection
RxNorm normalized name: CALCIUM GLUCONATE 23 g in 100 mL INTRAPERITONEAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal injection of DDP with sodium thiosulfate (STS) rescue
Trial: 3519886
Drug: PC (cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PC (cisplatin 50 mg/m2 + cyclophosphamide 600 mg/m2 on day 1 every 28 days)
Trial: 3519886
Drug: PAC (PC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAC (PC + doxorubicin 45 mg/m2)
Trial: 29631435
Drug: Dexamethasone 0.7
RxNorm normalized name: dexamethasone 0.7 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 0.7 mg at day 1 and month 5, with optional retreatment at month 10 or 11.
Trial: 29631435
Drug: Ranibizumab 0.5
RxNorm normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab 0.5 mg at day 1 and monthly through month 5, with as-needed injections at month 6-11.
Trial: 27406647
Drug: Coupled plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coupled plasma filtration adsorption (CPFA) with treated plasma ≥0.20 L/kg/day in the first 3 days after randomisation.
Trial: 18799820
Drug: Enalapril (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (20 mg/d, n = 30)
Trial: 18799820
Drug: Perindopril (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril (4 mg/d, n = 30)
Trial: 10480471
Drug: 81 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 81 mg/day ASA
Trial: 10480471
Drug: 325 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 325 mg/day ASA
Trial: 8531541
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment with Goretex bedcovers, benzyltannate spray, and a high‐filtration vacuum cleaner.
Trial: 8531541
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment with cotton covers, water spray, and a conventional domestic vacuum cleaner.
Trial: 1830393
Drug: Sodium chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium chloride treatment
Trial: 30700619
Drug: Programmed intermittent
RxNorm normalized name: Program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Programmed intermittent bolus infusion (PIBI) of 0.2% ropivacaine at 8 mL/h
Trial: 30700619
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion (CI) of 0.2% ropivacaine at 8 mL/h
Trial: 30700619
Drug: Programmed intermittent
RxNorm normalized name: Program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Programmed intermittent bolus infusion (PIBI) of 0.2% ropivacaine
Trial: 30700619
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion (CI) of 0.2% ropivacaine
Trial: 15682244
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose cotrimoxazole (4 mg trimethoprim plus 20 mg sulfamethoxazole/kg)
Trial: 15682244
Drug: Double dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dose cotrimoxazole (8 mg trimethoprim plus 40 mg sulfamethoxazole/kg)
Trial: 12692782
Drug: Intermittent androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent androgen deprivation (IAD) therapy
Trial: 10594485
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg TA orally
Trial: 10594485
Drug: 3.5 mg
RxNorm normalized name: niacin 13.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.5 mg glibenclamide orally
Trial: 10594485
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg TA+3.5 mg glibenclamide
Trial: 10594485
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg TA+50 mg acarbose
Trial: 1812314
Drug: tannalbuminate (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tannalbuminate (500 mg) and ethacridin‐lactate (50 mg), 1 tbl. b.i.d.
Trial: 6871776
Drug: Intraaortic protamine
RxNorm normalized name: protamines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraaortic protamine (3 mg . Kg‐1 injected over 30 sec)
Trial: 6871776
Drug: Intravenous protamine
RxNorm normalized name: protamines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous protamine (3 mg . Kg‐1 injected over 30 sec)
Trial: 30540966
Drug: Perioperative immunonutrition
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perioperative immunonutrition (oral supplementation enriched with arginine, ω‐3 fatty acids, and dietary nucleotides)
Trial: 24052490
Drug: Rotigotine transdermal
RxNorm normalized name: Rotigotine Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotigotine transdermal patch (2 mg/24 h) applied daily for 3 days
Trial: 21909730
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin D(3) 6,500 IU/day (20,000 IU twice per week + 800 IU/day)
Trial: 21909730
Drug: Standard-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose vitamin D(3) 800 IU/day (placebo twice per week + 800 IU/day)
Trial: 17956827
Drug: Once-daily LPV/r,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily LPV/r, tenofovir (TDF), and lamivudine (3TC)
Trial: 15885349
Drug: IFN-alpha treatment
RxNorm normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-alpha treatment without pre-emptive antidepressant therapy
Trial: 9793810
Drug: Lidocaine 1
RxNorm normalized name: lidocaine 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 1 mg/kg i.v.
Trial: 11527130
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Bisoprolol and Nifedipine
Trial: 28806095
Drug: Platelet-rich plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-rich plasma (PRP) injections at 7 and 14 days post-surgery